Patents by Inventor Joerg Holenz

Joerg Holenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190263747
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Applicant: GRUNENTHAL GMBH
    Inventors: WOLFGANG HELL, OSWALD ZIMMER, HELMUT HEINRICH BUSCHMANN, JÖRG HOLENZ, STEFAN GLADOW
  • Publication number: 20190135800
    Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Application
    Filed: February 10, 2017
    Publication date: May 9, 2019
    Inventors: Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
  • Patent number: 10053453
    Abstract: The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 21, 2018
    Assignee: AstraZeneca AB
    Inventors: Roland Bürli, Mark E. Duggan, Jörg Holenz, Patrik Johansson, Karin Kolmodin, Philip Vellacott Thorne, Michael John McKenzie
  • Patent number: 9850198
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: December 26, 2017
    Assignee: GRUENENTHAL GMBH
    Inventors: Helmut Heinrich Buschmann, Joerg Holenz
  • Publication number: 20170313686
    Abstract: The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
    Type: Application
    Filed: October 7, 2015
    Publication date: November 2, 2017
    Applicants: AstraZeneca AB, AstraZeneca AB
    Inventors: Roland Bürli, Mark E. Duggan, Jörg Holenz, Patrik Johansson, Karin Kolmodin, Philip Vellacott Thorne, Michael John McKenzie
  • Publication number: 20170217875
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Wolfgang HELL, Oswald ZIMMER, Helmut Heinrich BUSCHMANN, Jörg HOLENZ, Stefan GLADOW
  • Publication number: 20160257640
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Inventors: Helmut Heinrich BUSCHMANN, Joerg HOLENZ
  • Publication number: 20160221928
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Application
    Filed: April 12, 2016
    Publication date: August 4, 2016
    Inventors: Wolfgang HELL, Oswald ZIMMER, Helmut Heinrich BUSCHMANN, Jörg HOLENZ, Stefan GLADOW
  • Patent number: 9388119
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: July 12, 2016
    Assignee: GRUENENTHAL GMBH
    Inventors: Helmut Heinrich Buschmann, Joerg Holenz
  • Patent number: 9145380
    Abstract: The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: September 29, 2015
    Assignee: Astrazeneca AB
    Inventors: Johan Bylund, Maria E Ek, Ylva Gravenfors, Gunnar Nordvall, Alexander Minidis, Karl S. A Vallin, Jenny Viklund, Jörg Holenz, Stefan Von Berg, Daniel Sohn
  • Patent number: 8877974
    Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: November 4, 2014
    Assignee: Grünenthal GmbH
    Inventors: Wolfgang Hell, Oswald Zimmer, Helmut Heinrich Buschmann, Joerg Holenz, Stefan Gladow
  • Patent number: 8669399
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: March 11, 2014
    Assignee: Grünenthal GmbH
    Inventors: Helmut Heinrich Buschmann, Joerg Holenz
  • Publication number: 20130338399
    Abstract: A process for the preparation of substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds which has advantages over conventional processes with respect to higher conversions and yields, flexibility, a shorter overall route, environmentally acceptable conditions, influence of stereoselectivity such as diastereoselectivity in a targeted manner and at least partial suppression of the formation of undesired side-products and/or undesired stereoisomers, in particular undesired diastereomers.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 19, 2013
    Applicant: Gruenenthal GmbH
    Inventors: Helmut Heinrich BUSCHMANN, Joerg Holenz
  • Publication number: 20130296414
    Abstract: Metabolites of [2-(3-methoxyphenyl)-cyclohexylmethyl]dimethylamine as free bases and/or in the form of physiologically acceptable salts, corresponding medicaments, the use of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for producing a medicament used for treating depression, and related methods of treating depression, pain and urinary incontinence.
    Type: Application
    Filed: July 3, 2013
    Publication date: November 7, 2013
    Inventors: Elmar FRIDERICHS, Wolfgang STRASSBURGER, Ulrich JAHNEL, Helmut BUSCHMANN, Joerg HOLENZ, Oswald ZIMMER, Derek SAUNDERS, Werner ENGLBERGER, Hagen-Heinrich HENNIES
  • Patent number: 8557796
    Abstract: Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene compounds and processes for their production, the use thereof for producing pharmaceutical compositions, pharmaceutical compositions containing these compounds and methods of treatment using these compounds.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: October 15, 2013
    Assignee: Gruenenthal GmbH
    Inventors: Heinrich Helmut Buschmann, Guenter Werner Englberger, Tieno Germann, Hagen-Henrich Hennies, Corinna Maul, Bernd Sundermann, Joerg Holenz
  • Patent number: 8481567
    Abstract: The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: July 9, 2013
    Assignee: Laboratorios del Dr. Esteve, S.A.
    Inventors: Jordi Corbera-Arjona, David Vano-Domenech, Joerg Holenz
  • Patent number: 8470867
    Abstract: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: June 25, 2013
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Christian Laggner, María Rosa Cuberes-Altisent, Joerg Holenz, Juana María Berrocal-Romero, Maria Montserrat Contijoch-Llobet
  • Patent number: 8410159
    Abstract: The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: April 2, 2013
    Assignee: Laboratories del Dr. Esteve, S.A.
    Inventors: Rosa Cuberes-Altisent, Joerg Holenz
  • Patent number: 8394797
    Abstract: The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to pyrazole derivatives of formula I and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use therapy and prophylaxis, in particular for the treatment of psychosis or pain.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: March 12, 2013
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Jordi Corbera Arjona, Maria Rosa Cuberes-Altisent, Joerg Holenz, Daniel Martínez-Olmo, David Vaño-Domenech
  • Patent number: 8314096
    Abstract: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: November 20, 2012
    Assignee: Laboratorios del Dr. Esteve, S.A.
    Inventors: Christian Laggner, Maria Rosa Cuberes-Altisent, Joerg Holenz, Juana Maria Berrocal-Romero, Maria Montserrat Contijoch-Llobet